Enterprise ValueThe company still has a sizable negative enterprise value of over $200 million, despite the stock's positive movement.
Pipeline DevelopmentThere is low confidence that any early-stage immuno-oncology asset will add value for iTeos in the next year, as the investor bar for excitement is high.
Revenue PerformanceDuring 1Q25, the company reported no revenue, compared to the consensus estimate of $1.8M, and a net loss of $0.80 per share.